 Emily Su
Concepts (255)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Placenta | 19 | 2024 | 750 | 5.210 |
Why?
| | Fetal Growth Retardation | 13 | 2024 | 566 | 4.590 |
Why?
| | Endothelial Cells | 10 | 2023 | 785 | 2.530 |
Why?
| | Estrogen Receptor beta | 6 | 2012 | 40 | 1.840 |
Why?
| | Umbilical Arteries | 3 | 2024 | 55 | 1.730 |
Why?
| | Neovascularization, Physiologic | 4 | 2021 | 179 | 1.610 |
Why?
| | Pregnancy | 34 | 2025 | 6771 | 1.320 |
Why?
| | Premature Birth | 6 | 2024 | 333 | 1.170 |
Why?
| | Hypertension, Pregnancy-Induced | 5 | 2024 | 69 | 1.140 |
Why?
| | Hypertension | 10 | 2025 | 1298 | 1.130 |
Why?
| | Pregnancy Complications, Cardiovascular | 8 | 2025 | 77 | 1.120 |
Why?
| | Aryl Hydrocarbon Receptor Nuclear Translocator | 2 | 2019 | 17 | 1.090 |
Why?
| | Antihypertensive Agents | 8 | 2025 | 494 | 1.060 |
Why?
| | Endometriosis | 6 | 2012 | 51 | 0.990 |
Why?
| | Chorionic Villi | 2 | 2024 | 25 | 0.890 |
Why?
| | Integrin alphaVbeta3 | 1 | 2022 | 18 | 0.790 |
Why?
| | Cell Movement | 4 | 2021 | 967 | 0.760 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 3 | 2022 | 71 | 0.720 |
Why?
| | Otoacoustic Emissions, Spontaneous | 1 | 2020 | 5 | 0.700 |
Why?
| | Acoustic Impedance Tests | 1 | 2020 | 13 | 0.690 |
Why?
| | Artificial Intelligence | 1 | 2024 | 282 | 0.670 |
Why?
| | Prostaglandins | 2 | 2011 | 97 | 0.660 |
Why?
| | Neovascularization, Pathologic | 2 | 2019 | 301 | 0.650 |
Why?
| | Pre-Eclampsia | 6 | 2024 | 190 | 0.630 |
Why?
| | Progesterone | 4 | 2010 | 254 | 0.610 |
Why?
| | Uveomeningoencephalitic Syndrome | 1 | 2019 | 7 | 0.610 |
Why?
| | Fetus | 5 | 2023 | 806 | 0.610 |
Why?
| | 17-Hydroxysteroid Dehydrogenases | 2 | 2010 | 5 | 0.600 |
Why?
| | Panuveitis | 1 | 2019 | 7 | 0.600 |
Why?
| | Estrogens | 2 | 2012 | 367 | 0.600 |
Why?
| | Adalimumab | 1 | 2019 | 48 | 0.600 |
Why?
| | Female | 46 | 2025 | 73465 | 0.560 |
Why?
| | Pregnancy Outcome | 7 | 2024 | 416 | 0.540 |
Why?
| | Extracellular Matrix | 1 | 2021 | 528 | 0.530 |
Why?
| | Benzo(a)pyrene | 1 | 2016 | 8 | 0.510 |
Why?
| | Cyclooxygenase 2 | 3 | 2016 | 178 | 0.500 |
Why?
| | Endothelium, Vascular | 5 | 2018 | 927 | 0.490 |
Why?
| | Vascular Endothelial Growth Factor A | 6 | 2022 | 545 | 0.490 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2016 | 55 | 0.490 |
Why?
| | Signal Transduction | 5 | 2019 | 5081 | 0.450 |
Why?
| | Endometrium | 4 | 2012 | 58 | 0.430 |
Why?
| | Humans | 49 | 2025 | 137782 | 0.420 |
Why?
| | Reproduction | 2 | 2012 | 204 | 0.410 |
Why?
| | Umbilical Cord | 1 | 2013 | 85 | 0.390 |
Why?
| | Cell Proliferation | 2 | 2018 | 2475 | 0.390 |
Why?
| | Stillbirth | 1 | 2013 | 72 | 0.390 |
Why?
| | Fetal Diseases | 1 | 2013 | 173 | 0.360 |
Why?
| | Infant, Newborn | 13 | 2025 | 6084 | 0.350 |
Why?
| | Endothelium | 1 | 2011 | 123 | 0.350 |
Why?
| | Birth Weight | 4 | 2025 | 516 | 0.350 |
Why?
| | Ultrasonography, Doppler | 2 | 2024 | 125 | 0.320 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2007 | 283 | 0.310 |
Why?
| | Women's Health | 1 | 2012 | 372 | 0.300 |
Why?
| | Estradiol | 3 | 2011 | 521 | 0.290 |
Why?
| | Infant, Small for Gestational Age | 2 | 2025 | 92 | 0.280 |
Why?
| | Promegestone | 1 | 2007 | 33 | 0.270 |
Why?
| | Postpartum Period | 3 | 2024 | 340 | 0.270 |
Why?
| | Adult | 18 | 2025 | 38023 | 0.270 |
Why?
| | Up-Regulation | 3 | 2019 | 843 | 0.250 |
Why?
| | Estrogen Receptor alpha | 3 | 2012 | 145 | 0.240 |
Why?
| | Fetal Development | 2 | 2023 | 296 | 0.240 |
Why?
| | Pregnancy Trimester, Third | 1 | 2025 | 115 | 0.230 |
Why?
| | Chronic Disease | 7 | 2025 | 1794 | 0.230 |
Why?
| | Placental Circulation | 2 | 2017 | 71 | 0.220 |
Why?
| | Labetalol | 1 | 2024 | 6 | 0.220 |
Why?
| | Nifedipine | 1 | 2024 | 29 | 0.220 |
Why?
| | Case-Control Studies | 4 | 2021 | 3569 | 0.220 |
Why?
| | Hip Fractures | 1 | 2025 | 86 | 0.220 |
Why?
| | Hypotension | 1 | 2025 | 122 | 0.220 |
Why?
| | Uterus | 2 | 2017 | 215 | 0.210 |
Why?
| | Delivery, Obstetric | 1 | 2024 | 144 | 0.200 |
Why?
| | Gestational Age | 5 | 2024 | 910 | 0.200 |
Why?
| | Cost of Illness | 1 | 2025 | 308 | 0.200 |
Why?
| | Integrin alpha5beta1 | 1 | 2022 | 9 | 0.200 |
Why?
| | Breast Feeding | 2 | 2024 | 440 | 0.200 |
Why?
| | Regional Blood Flow | 2 | 2017 | 481 | 0.200 |
Why?
| | Cannabidiol | 1 | 2024 | 119 | 0.200 |
Why?
| | Pregnancy in Diabetics | 1 | 2024 | 123 | 0.190 |
Why?
| | Cells, Cultured | 5 | 2021 | 4193 | 0.190 |
Why?
| | Epoprostenol | 2 | 2016 | 136 | 0.190 |
Why?
| | Extracellular Matrix Proteins | 1 | 2023 | 153 | 0.190 |
Why?
| | Stromal Cells | 3 | 2012 | 112 | 0.190 |
Why?
| | Dronabinol | 1 | 2024 | 230 | 0.190 |
Why?
| | Fibronectins | 1 | 2022 | 133 | 0.190 |
Why?
| | Furin | 1 | 2021 | 14 | 0.180 |
Why?
| | Trophoblasts | 2 | 2021 | 199 | 0.180 |
Why?
| | Reperfusion Injury | 1 | 2023 | 279 | 0.180 |
Why?
| | Otoscopy | 1 | 2020 | 8 | 0.170 |
Why?
| | Receptors, Virus | 1 | 2021 | 83 | 0.170 |
Why?
| | New Zealand | 1 | 2020 | 56 | 0.170 |
Why?
| | Steroidogenic Factor 1 | 2 | 2012 | 12 | 0.170 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 84 | 0.170 |
Why?
| | Serine Endopeptidases | 1 | 2021 | 123 | 0.170 |
Why?
| | Receptors, Progesterone | 3 | 2012 | 350 | 0.170 |
Why?
| | Cohort Studies | 4 | 2024 | 5750 | 0.160 |
Why?
| | Models, Biological | 2 | 2017 | 1783 | 0.160 |
Why?
| | RNA Interference | 3 | 2011 | 469 | 0.160 |
Why?
| | Triamcinolone | 1 | 2019 | 17 | 0.150 |
Why?
| | Hospitalization | 2 | 2025 | 2200 | 0.150 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2018 | 86 | 0.140 |
Why?
| | Hypertension, Pulmonary | 2 | 2022 | 1910 | 0.140 |
Why?
| | Mycophenolic Acid | 1 | 2019 | 118 | 0.140 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2024 | 605 | 0.140 |
Why?
| | Remission Induction | 1 | 2019 | 289 | 0.140 |
Why?
| | Fluorescein Angiography | 1 | 2019 | 151 | 0.140 |
Why?
| | Headache | 1 | 2019 | 147 | 0.140 |
Why?
| | Gene Expression Regulation | 3 | 2012 | 2607 | 0.140 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 976 | 0.130 |
Why?
| | Fetal Blood | 2 | 2017 | 327 | 0.130 |
Why?
| | Blood Pressure | 4 | 2025 | 1789 | 0.130 |
Why?
| | Systems Biology | 1 | 2017 | 67 | 0.130 |
Why?
| | Tomography, Optical Coherence | 1 | 2019 | 213 | 0.130 |
Why?
| | Research Design | 1 | 2023 | 1139 | 0.130 |
Why?
| | Pluripotent Stem Cells | 1 | 2017 | 80 | 0.130 |
Why?
| | Morphogenesis | 1 | 2017 | 166 | 0.130 |
Why?
| | Organoids | 1 | 2017 | 112 | 0.130 |
Why?
| | Feasibility Studies | 1 | 2020 | 963 | 0.130 |
Why?
| | Mental Disorders | 1 | 2025 | 1077 | 0.130 |
Why?
| | Visual Acuity | 1 | 2019 | 356 | 0.130 |
Why?
| | Lab-On-A-Chip Devices | 1 | 2016 | 41 | 0.130 |
Why?
| | Substance-Related Disorders | 1 | 2025 | 1083 | 0.120 |
Why?
| | Epigenesis, Genetic | 2 | 2012 | 660 | 0.120 |
Why?
| | Acute Kidney Injury | 1 | 2023 | 815 | 0.120 |
Why?
| | Drug Therapy, Combination | 1 | 2019 | 1067 | 0.120 |
Why?
| | Cesarean Section | 3 | 2024 | 184 | 0.120 |
Why?
| | Maternal-Fetal Exchange | 1 | 2016 | 165 | 0.120 |
Why?
| | Cilia | 1 | 2017 | 178 | 0.120 |
Why?
| | Blood Flow Velocity | 1 | 2015 | 420 | 0.110 |
Why?
| | Cell Cycle | 1 | 2017 | 601 | 0.110 |
Why?
| | Abruptio Placentae | 2 | 2024 | 5 | 0.100 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2019 | 1242 | 0.100 |
Why?
| | Growth Disorders | 1 | 2014 | 86 | 0.100 |
Why?
| | Vascular Resistance | 1 | 2015 | 375 | 0.100 |
Why?
| | Infant, Premature | 2 | 2017 | 574 | 0.100 |
Why?
| | Fetal Distress | 1 | 2012 | 13 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2010 | 1396 | 0.100 |
Why?
| | Ovarian Diseases | 1 | 2012 | 12 | 0.100 |
Why?
| | Oogenesis | 1 | 2012 | 20 | 0.090 |
Why?
| | Ovulation | 1 | 2012 | 40 | 0.090 |
Why?
| | Placentation | 1 | 2012 | 45 | 0.090 |
Why?
| | Estrogen Antagonists | 1 | 2012 | 45 | 0.090 |
Why?
| | Chorioamnionitis | 1 | 2012 | 42 | 0.090 |
Why?
| | Eicosanoids | 1 | 2012 | 62 | 0.090 |
Why?
| | Retrospective Studies | 3 | 2025 | 15682 | 0.090 |
Why?
| | Pregnancy Proteins | 1 | 2012 | 36 | 0.090 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2017 | 383 | 0.090 |
Why?
| | Muscle Tonus | 1 | 2011 | 21 | 0.090 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2011 | 77 | 0.090 |
Why?
| | Parturition | 1 | 2012 | 71 | 0.090 |
Why?
| | Metabolic Networks and Pathways | 1 | 2012 | 180 | 0.090 |
Why?
| | Ultrasonography | 1 | 2015 | 763 | 0.090 |
Why?
| | Animals | 7 | 2023 | 36951 | 0.080 |
Why?
| | Large Neutral Amino Acid-Transporter 1 | 1 | 2010 | 14 | 0.080 |
Why?
| | Vasoconstriction | 1 | 2011 | 202 | 0.080 |
Why?
| | Placenta Growth Factor | 2 | 2022 | 24 | 0.080 |
Why?
| | Myometrium | 1 | 2010 | 39 | 0.080 |
Why?
| | Prospective Studies | 4 | 2024 | 7623 | 0.080 |
Why?
| | Child, Preschool | 2 | 2024 | 11105 | 0.080 |
Why?
| | Leiomyoma | 1 | 2010 | 77 | 0.080 |
Why?
| | Paracrine Communication | 1 | 2010 | 65 | 0.080 |
Why?
| | Thromboxanes | 1 | 2009 | 17 | 0.080 |
Why?
| | Apoptosis | 1 | 2018 | 2553 | 0.080 |
Why?
| | Uterine Neoplasms | 1 | 2010 | 109 | 0.080 |
Why?
| | Molecular Targeted Therapy | 1 | 2012 | 411 | 0.070 |
Why?
| | Blotting, Western | 1 | 2011 | 1227 | 0.070 |
Why?
| | Neoplasm Proteins | 1 | 2012 | 434 | 0.070 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2010 | 261 | 0.070 |
Why?
| | Vasodilation | 1 | 2011 | 499 | 0.070 |
Why?
| | Retinoid X Receptor alpha | 1 | 2007 | 4 | 0.070 |
Why?
| | Progesterone Congeners | 1 | 2007 | 16 | 0.070 |
Why?
| | Glucocorticoids | 1 | 2012 | 596 | 0.070 |
Why?
| | Retinoic Acid Receptor alpha | 1 | 2007 | 17 | 0.070 |
Why?
| | Receptors, Retinoic Acid | 1 | 2007 | 43 | 0.070 |
Why?
| | Aromatase | 1 | 2007 | 32 | 0.070 |
Why?
| | Cell Differentiation | 2 | 2017 | 1991 | 0.070 |
Why?
| | Breast Neoplasms | 2 | 2012 | 2253 | 0.070 |
Why?
| | Promoter Regions, Genetic | 1 | 2012 | 1251 | 0.070 |
Why?
| | Immunohistochemistry | 1 | 2011 | 1738 | 0.070 |
Why?
| | Immunoblotting | 1 | 2007 | 308 | 0.060 |
Why?
| | Fluorescent Antibody Technique | 1 | 2007 | 390 | 0.060 |
Why?
| | Databases, Factual | 1 | 2011 | 1357 | 0.060 |
Why?
| | Endometrial Neoplasms | 1 | 2007 | 201 | 0.060 |
Why?
| | Arterial Pressure | 1 | 2024 | 128 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2010 | 2834 | 0.050 |
Why?
| | Kidney Tubules, Proximal | 1 | 2023 | 128 | 0.050 |
Why?
| | Mice | 3 | 2023 | 17794 | 0.050 |
Why?
| | Kidney | 2 | 2023 | 1475 | 0.050 |
Why?
| | Biomarkers | 3 | 2022 | 4154 | 0.050 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2022 | 79 | 0.050 |
Why?
| | Triage | 1 | 2024 | 224 | 0.050 |
Why?
| | Administration, Oral | 1 | 2024 | 816 | 0.050 |
Why?
| | Fetal Hypoxia | 1 | 2022 | 54 | 0.050 |
Why?
| | Virus Internalization | 1 | 2021 | 49 | 0.040 |
Why?
| | Ovarian Neoplasms | 1 | 2007 | 565 | 0.040 |
Why?
| | Male | 5 | 2025 | 67906 | 0.040 |
Why?
| | Child Development | 1 | 2024 | 475 | 0.040 |
Why?
| | Length of Stay | 1 | 2025 | 1215 | 0.040 |
Why?
| | Proteome | 1 | 2023 | 472 | 0.040 |
Why?
| | Child | 1 | 2019 | 21989 | 0.040 |
Why?
| | Prevalence | 1 | 2025 | 2734 | 0.040 |
Why?
| | Patient Acceptance of Health Care | 1 | 2024 | 807 | 0.040 |
Why?
| | Synthetic Biology | 1 | 2017 | 11 | 0.030 |
Why?
| | Altitude | 1 | 2022 | 488 | 0.030 |
Why?
| | Transcriptome | 1 | 2023 | 972 | 0.030 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2017 | 25 | 0.030 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2017 | 74 | 0.030 |
Why?
| | Phosphatidylinositol 4,5-Diphosphate | 1 | 2017 | 32 | 0.030 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2021 | 394 | 0.030 |
Why?
| | Phosphoric Monoester Hydrolases | 1 | 2017 | 54 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2022 | 2041 | 0.030 |
Why?
| | NIH 3T3 Cells | 1 | 2017 | 144 | 0.030 |
Why?
| | Middle Aged | 3 | 2013 | 33554 | 0.030 |
Why?
| | Microvilli | 1 | 2016 | 78 | 0.030 |
Why?
| | Proof of Concept Study | 1 | 2016 | 78 | 0.030 |
Why?
| | Infant, Extremely Premature | 1 | 2017 | 66 | 0.030 |
Why?
| | Body Mass Index | 1 | 2024 | 2390 | 0.030 |
Why?
| | Models, Animal | 1 | 2017 | 384 | 0.030 |
Why?
| | Cell Communication | 1 | 2017 | 315 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2016 | 239 | 0.030 |
Why?
| | United States | 2 | 2025 | 14870 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 305 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2016 | 325 | 0.030 |
Why?
| | Single-Cell Analysis | 1 | 2017 | 313 | 0.030 |
Why?
| | Equipment Design | 1 | 2016 | 522 | 0.030 |
Why?
| | Actins | 1 | 2017 | 416 | 0.030 |
Why?
| | Adolescent | 1 | 2013 | 21574 | 0.030 |
Why?
| | Time Factors | 1 | 2024 | 6834 | 0.030 |
Why?
| | Tissue Engineering | 1 | 2017 | 423 | 0.030 |
Why?
| | Proteomics | 1 | 2020 | 1111 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2023 | 4295 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2025 | 7637 | 0.030 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 2072 | 0.020 |
Why?
| | Young Adult | 2 | 2024 | 13240 | 0.020 |
Why?
| | Cardiotocography | 1 | 2012 | 3 | 0.020 |
Why?
| | Fetal Monitoring | 1 | 2012 | 15 | 0.020 |
Why?
| | Heart Rate, Fetal | 1 | 2012 | 21 | 0.020 |
Why?
| | Genomics | 1 | 2017 | 795 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2012 | 117 | 0.020 |
Why?
| | Infant | 1 | 2024 | 9482 | 0.020 |
Why?
| | Cell Line | 1 | 2016 | 2847 | 0.020 |
Why?
| | Mifepristone | 1 | 2010 | 64 | 0.020 |
Why?
| | Hormone Antagonists | 1 | 2010 | 34 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2024 | 10837 | 0.020 |
Why?
| | CpG Islands | 1 | 2010 | 157 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2860 | 0.020 |
Why?
| | Acute Disease | 1 | 2012 | 1007 | 0.020 |
Why?
| | Dinoprostone | 1 | 2008 | 191 | 0.020 |
Why?
| | Cell Survival | 1 | 2010 | 1120 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2010 | 2057 | 0.020 |
Why?
| | Aged | 1 | 2025 | 24001 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2012 | 1775 | 0.010 |
Why?
| | DNA Methylation | 1 | 2010 | 643 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2012 | 2836 | 0.010 |
Why?
| | Transcription Factors | 1 | 2008 | 1719 | 0.010 |
Why?
| | Inflammation | 1 | 2008 | 2838 | 0.010 |
Why?
|
|
Su's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|